A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors

J Infect Dis. 1992 Oct;166(4):904-7. doi: 10.1093/infdis/166.4.904.


Clinical isolates of human cytomegalovirus (HCMV) were screened for susceptibility to ganciclovir by plaque-reduction assay and in situ ELISA. A pretreatment isolate of HCMV obtained from the bronchial brushing of a heart transplant recipient contained both ganciclovir-susceptible and -resistant virus. Ganciclovir-susceptible (P8) and -resistant (D16) strains were further isolated by plaque purification. Both strains phosphorylated ganciclovir at levels similar to the ganciclovir-susceptible strain AD169. D16 was also resistant to phosphonoformic acid and to (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and cytosine. These data suggest that the resistance of D16 to these drugs results from a mutation in the viral DNA polymerase gene.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Chromatography, High Pressure Liquid
  • Cytomegalovirus / drug effects*
  • Cytomegalovirus / growth & development
  • Drug Resistance, Microbial
  • Enzyme-Linked Immunosorbent Assay / methods
  • Foscarnet
  • Ganciclovir / pharmacology*
  • Humans
  • Nucleic Acid Synthesis Inhibitors*
  • Phosphonoacetic Acid / analogs & derivatives
  • Phosphonoacetic Acid / pharmacology
  • Viral Plaque Assay / methods


  • Antiviral Agents
  • Nucleic Acid Synthesis Inhibitors
  • Foscarnet
  • Phosphonoacetic Acid
  • Ganciclovir